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Abstract
Background: Both rising healthcare costs and the global financial crisis have fueled a search for 
policy tools in order to avoid unsustainable future financing of essential health benefits. The scope of 
essential health benefits (the range of services covered) and depth of coverage (the proportion of costs 
of the covered benefits that is covered publicly) are corresponding variables in determining the benefits 
package. We hypothesized that a more comprehensive health benefit package may increase user cost-
sharing charges.
Methods: We conducted a desktop research study to assess the interrelationship between the scope 
of covered health benefits and the height of statutory spending in a sample of 8 European countries: 
Belgium, England, France, Germany, the Netherlands, Scotland, Sweden, and Switzerland. We conducted 
a targeted literature search to identify characteristics of the healthcare systems in our sample of countries. 
We analyzed similarities and differences based on the dimensions of publicly financed healthcare as 
published by the European Observatory on Health Care Systems. 
Results: We found that the scope of services is comparable and comprehensive across our sample, with 
only marginal differences. Cost-sharing arrangements show the most variation. In general, we found 
no direct interrelationship in this sample between the ranges of services covered in the health benefits 
package and the height of public spending on healthcare. With regard to specific services (dental care, 
physical therapy), we found indications of an association between coverage of services and cost-sharing 
arrangements. Strong variations in the volume and price of healthcare services between the 8 countries 
were found for services with large practice variations. 
Conclusion: Although reducing the scope of the benefit package as well as increasing user charges may 
contribute to the financial sustainability of healthcare, variations in the volume and price of care seem 
to have a much larger impact on financial sustainability. Policy-makers should focus on a variety of 
measures within an integrated approach. There is no silver bullet for addressing the sustainability of 
healthcare.
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Implications for policy makers
• Reduction of the scope of the benefit package and an increase of user charges has limited impact on the reduction of the volume and cost of 
care at the macro level. Supply constraints may have a much larger impact on reducing the volume of care and thus the long-term financial 
sustainability of public healthcare provision.
• Policy-makers should focus on a variety of measures within an integrated approach, including considerations for services covered, cost-
sharing arrangements, stimulating evidence-based practice, the monitoring and reduction of unwarranted variation, and control mechanisms 
for the price of healthcare services.
Implications for public
Coverage for healthcare services funded by public revenues in our sample of 8 European countries is comparable and comprehensive, with only 
marginal differences. It is the cost-sharing arrangements for citizens that vary the most, and they imply different thresholds for individual access 
to specific health services in the selected countries.
Key Messages 
   View Video Summary
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Background
Rising healthcare costs are leading to major sustainability 
issues in healthcare systems around the world. In addition, 
the global financial crisis has reduced the availability of health 
system resources. As a result, many European countries 
have implemented policy tools to address these financial 
challenges.1,2 In the United States, criteria for essential health 
benefits have been developed to cover health services that are 
medically effective and affordable for purchasers.3 Healthcare 
spending is a function of price and quantity (volume), and 
controlling costs therefore requires controlling the price 
and/or volume.4 Strategies for enhancing the financial 
sustainability of health systems may be aimed at reducing 
the demand for healthcare, reducing the supply of healthcare 
provisions, or controlling the price of healthcare services. 
However, proposed policy tools such as reducing the scope 
of essential services covered, reducing population coverage 
and user charges for essential services, risk undermining 
important goals of the health system, such as access and 
solidarity.1 
The scope of essential health benefits (the range of services 
covered) and depth of coverage (the proportion of costs of 
the covered benefits that is publicly covered) are hypothesized 
as corresponding variables in determining the benefits 
package. In other words, a generous benefits package (wide 
range of service coverage) may correspond with high private 
financial contributions (low coverage depth), while a limited 
benefits package may correspond with high coverage depth.5,6 
Understanding the potential interrelationships between these 
variables may help policy-makers enhance the financial 
sustainability of healthcare. Both a reduction in the scope 
of the benefits package, and an increase in user charges for 
health services are often advocated as (effective) means for 
cost control. 
 In an effort to safeguard the financial sustainability of publicly 
supported healthcare, countries have employed a variety of 
initiatives in redefining the benefit package. In England, The 
National Institute for Health and Care Excellence (NICE) 
has developed a list of ‘do not do’ recommendations with 
the aim of excluding specific services.7 In Australia, the 
Comprehensive Management Framework was developed to 
assess health services for effectiveness, safety, and monetary 
value.8 In the Netherlands, there is an ongoing debate about 
the further establishment of rigorous evaluations of essential 
health benefits.9 In the United States, essential health benefits 
are offered under the Affordable Care Act (ACA), with latitude 
at the state level to define essential benefits by choosing a 
benchmark plan modeled on existing state plans.10,11 
User charges are an often-cited policy measure for cost-
containment. The RAND Health Insurance Experiment in 
the Unites States showed that user charges reduced the use 
of medical care, although this reduction was related to both 
inappropriate (unnecessary) and appropriate (necessary) use 
of care.12 User charges have the potential to reduce overuse 
or unnecessary care.13 As such, user charges are an attempt to 
better match demand and supply.14 As a response to the global 
financial crisis, at least sixteen countries reported introducing 
or increasing user charges for a variety of services.2 However, 
the impact of varying user charges on appropriate use of care 
is as yet unclear. 
In this study, we hypothesized that the scope of  health benefits 
is related to the level of user charges for covered benefits. The 
aim of our study was to assess the interrelationship between 
the scope of coverage and the financial arrangements of 
statutory financed healthcare in European countries. 
Policy-makers can use such information to further address 
issues relevant to enhancing financial sustainability, and for 
modifying essential health benefits, for example through 
mapping possible trade-off effects between publicly funded 
benefits and private contributions. We specified 2 research 
questions to address our objectives:
1.	 What are the scope of health benefits and the financing 
of statutory financed healthcare within European 
countries?
2.	 What is the interrelationship between the scope of 
health benefits and financial arrangements of statutory 
financed healthcare?
Methods
Study Design and Setting
We conducted a desktop research study to compare a sample 
of European countries with varied healthcare systems and 
characteristics. Our sample included 8 countries: Belgium, 
England, France, Germany, the Netherlands, Scotland, Sweden, 
and Switzerland. Three of these countries (England, Scotland, 
and Sweden) operate a National Health Service (NHS), while 
5 countries (Belgium, France, Germany, the Netherlands, and 
Switzerland) operate a system of social health insurance (SHI). 
This sample shows variations in approaches to healthcare 
coverage, such as national vs. regional approaches, public 
vs. private financing, and (managed) competition vs. no 
competition. Table 1 summarizes the main characteristics of 
the healthcare systems in these 8 countries.
Outcomes 
We developed outcomes based on the dimensions of 
publicly financed healthcare as published by the European 
Observatory on Health Care Systems. These dimensions were 
initially developed in the Health BASKET study,4,5 and were 
further specified for the series Health Systems in Transition 
of the Observatory.15 The 3 dimensions are: (1) population 
coverage, ie, the proportion of the population that is covered 
for healthcare; (2) service coverage, ie, the scope of healthcare 
benefits that are covered; and (3) cost coverage, ie, the 
proportion of costs that is covered for included healthcare 
benefits (see Figure 1). These 3 dimensions were further 
operationalized, resulting in indicators related to population 
coverage: SHI or NHS, assignment procedure, percentage 
of population covered; service coverage: open or closed 
description of benefits, main benefits in public scheme; and 
cost coverage: total spending, public vs. private funding, cost 
sharing. The focus of our study was to compare essential 
health benefits for curative care, thus excluding long-term 
care and public health services. However, the distinction 
between these services is not always clear-cut, and we have 
clarified this in the results when relevant.
Literature Review
We conducted a targeted literature search to identify the 
main characteristics of the healthcare systems in our sample 
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of countries. We used several data sources known for their 
review of healthcare systems: Health Systems in Transition 
of the European Observatory on Health Care Systems,16-23 
International Profiles of Health Care Systems of The 
Commonwealth Fund,24 the Mutual Information System on 
Social Protection (MISSOC) of the European Union (EU),25 
reports of the Civitas Health Unit,26-28 and reports of the 
Organization of Economic Cooperation and Development 
(OECD).29,30 For quantitative comparisons, we used OECD 
Health Data,31 3 International Health Policy surveys of the 
Commonwealth Fund,32-34 and SHARE surveys.35 
In addition, we conducted a targeted literature search in 
PubMed and Google Scholar to find both peer-reviewed 
publications and grey literature. We employed a wide-
angle approach using combinations of the following search 
terms: healthcare systems, health benefits, healthcare access, 
governance, workforce planning, healthcare financing, public 
financing, private financing, healthcare costs, healthcare 
premiums, deductibles, co-payments – in combination with 
the names of the 8 countries in our sample. We also used policy 
documents, websites and information from key informants in 
our network. The literature for our data analysis was searched 
until December 2014.
Data Analysis and Synthesis
In comparing the sample of 8 countries, we used both 
qualitative and quantitative data to inform the description 
Table 1. Characteristics of Healthcare Systems in the Selected 8 European Countriesa
BE ENG FR GE NL SC SWE SWI
SHI/NHS SHI NHS SHI SHI SHI NHS NHS SHI
National/regional REG REG REG NA NA REG REG REG
Benefits in kind/indemnity B/I B B B/I B/I B B B/I
Vertical integration NO YES NO NO NO YES NO NO
Selective purchasing * * * ** *** NO * **
Competition * * * ** *** * * ***
Benefits: control government *** *** ** ** ** *** *** *
Private financing ** * *** ** ** * * ***
Abbreviations: SHI, social health insurance; NHS, National Health Service; NA, National; REG, Regional; B, Benefits in kind – the insurer makes payments directly 
to the healthcare provider; I, Indemnity – the insured pays out-of-pocket and is then reimbursed by the insurer; BE, Belgium; ENG, England; FR, France; GE, 
Germany; NL, the Netherlands; SC, Scotland; SWE, Sweden; SWI, Switzerland.
*** = high; ** = average; * = low.
a General typology based on key characteristics of healthcare systems.
Figure 1. The Three Dimensions of Publicly Financed Healthcare.15
of the healthcare system for the specified outcomes as of the 
year 2013. We analyzed similarities and differences in the 3 
dimensions of statutory financed healthcare systems to assess 
interrelationships between the comprehensiveness of health 
benefits and financial arrangements. In addition, we explored 
2 main variables that may interact with the 3 dimensions of 
healthcare systems: variations in volume (use of healthcare 
services), and price (costs of healthcare services).
Results 
Population Coverage
Five countries in our sample (Belgium, France, Germany, the 
Netherlands, and Switzerland) operate a system of mandatory 
SHI for their residents. In each of these countries, population 
coverage is more than 99%. In the Netherlands and 
Switzerland, residents are required to contract with a health 
insurer of their own choice, based on managed competition 
of insurers via national and regional health exchanges, 
respectively.36 Residents in France are ‘assigned’ to one of 
the SHI companies, eg, through their employer. In Belgium 
and Germany, health insurance is obligatory for all citizens 
and permanent residents. Contrary to the Netherlands and 
Switzerland, German and Belgian beneficiaries in principle 
get household insurance. However, they are also free to choose 
their insurers or sickness funds, and may switch periodically.37 
Residents of England, Scotland and Sweden are automatically 
covered through their NHS systems. 
Service Coverage
Service coverage is specified in a health benefits basket that 
describes the publicly financed care accessible to all residents 
via SHI or NHS. Service coverage can be specified through 
2 approaches: (a) an ‘open specification’ with a general 
(functional) description of benefits outlining eligibility for 
these benefits, and (b) ‘closed specification’ with detailed 
(positive) listings of all benefits that are covered through 
public financing.6,15 Open systems may also use negative 
listings of services that are not covered. Belgium and France 
have a closed specification system with positive listings 
of 7000-8500 covered benefits. Germany also uses lists 
of benefits, but these are less detailed and not available for 
the full spectrum of healthcare. England, Scotland, the 
Netherlands, Sweden, and Switzerland use negative listings of 
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services that are not covered. Coverage of prescriptions drugs 
is separately described in the 8 countries, with positive listings 
in 5 countries (Belgium, France, the Netherlands, Sweden, 
Switzerland), and negative listings in 3 countries (Germany, 
England, Scotland).
Table 2 presents the main benefits for adults in the 8 
countries of our sample. All countries cover regular medical 
services, and exclude cosmetic surgery. We found only 
small differences between the countries. Examples of such 
differences are related to specific services such as dental care, 
physical therapy, and prescription drugs. Routine dental care 
for adults is not covered in the Netherlands and Switzerland, 
while these services are covered in the other countries. In the 
Netherlands, primary care and physical therapy for adults 
is partially covered (after 20 treatment sessions) for certain 
chronic conditions. In Switzerland, nine treatment sessions 
are covered within 3 months upon referral. In England and 
Scotland, physical therapy is fully covered, while Belgium, 
Germany, France, and Sweden charge co-payments for 
physical therapy treatments. The limited coverage for health 
services may be related to potential coverage outside the 
curative care system. For example, in the Netherlands physical 
therapy services for residents in nursing homes are covered 
through the long-term care budget. 
Cost Coverage
Financial data for healthcare in the 8 countries is listed in 
Table 3. The Netherlands has the highest relative costs of total 
healthcare with 11.9% of the gross domestic product (GDP), 
while the costs for the cure sector (ie, without long-term care 
and home care) in the Netherlands are, with 7.4% of GDP, 
the lowest in our sample. Table 3 also shows the relative 
costs of public vs. private funding. Private funding includes 
private insurance, direct payments for noncovered services, 
and cost-sharing for covered health services. Two main 
groups can be identified in comparing the shares of private 
funding. England, Germany, France, the Netherlands, and 
Scotland show a relative low percentage, ranging from 9.6% 
to 11.9%. The share of private funding in Belgium, Sweden 
and Switzerland is higher and varies from 19.5% to 25.5%.
Table 2. Health Services for Adults Covered by Public Financinga
Services BE ENG FR GE NL SC SWE SWI
Primary care physician Y Y Y Y Y Y Y Y
Medical specialist Y Y Y Y Y Y Y Y
Maternal care Y Y Y Y Y Y Y Y
Hospital care Y Y Y Y Y Y Y Y
Rehabilitation Y Y Y Y Y Y Y Y
Prevention Y Y Y Y Y Y Y Y
Dental care Y Y Y Y N Y Y N
Mental healthcare Y Y Y Y Y Y Y Y
Physical therapy Y Y Y Y Sb Y Y Y
Occupational therapy Y Y Y Y Y Y Y Y
Speech therapy Y Y Y Y Y Y Y Y
Medical devices Y Y Y Y Y Y Y Y
Cosmetic surgery N N N N N N N N
Abbreviations: NL, the Netherlands; BE, Belgium; GE, Germany; ENG, England; FR, France; SC, Scotland; SWE, Sweden, SWI, Switzerland; Y, Yes; N, No.
a Comparisons in this table refer to adults aged 19-60 without chronic disease or low income.
b S=Specification: Only covered for certain chronic conditions after 20 sessions.
Sources: Health Systems in Transition, European Observatory on Health Care Systems; International Profiles of Health Care Systems 2012, The Commonwealth 
Fund; MISSOC; WHO Medicines Documentation (http://apps.who.int/medicinedocs/en/d/Jh2943e/11.3.html).
Table 3. Financial Data (2011)   
Costs BE ENG FR GE NL SC SWE SWI
Total healthcare costs as % GDP 10.5 9.4 11.6 11.3 11.9 9.4 9.5 11.0
Curative sector as % GDPa 7.7 - 9.1 8.6 7.4 - 7.7 8.1
Curative sector ($ PPP)a 2978 - 3230 3421 3171 - 3181 4155
Prescription drugs (% healthcare) 15.5 11.4 15.6 14.1 9.4 11.4 12.1 9.4
Per capita prescription drugs (€) 630 374 641 632 479 374 474 530
Financing of curative sectorb
% Collective (government, social security) 71.1 82.8 76.8 77.7 78.5c 82.8 80.5 64.9
% Private (OUPd, private insurance, other) 28.9 17.2 23.3 22.3 21.5c 17.2 19.5 35.1
% Private OUPd 25.0 9.9 9.6 11.7 11.9c 9.9 19.5 25.5
Abbreviations: NL, the Netherlands; BE, Belgium; GE, Germany; ENG, England; FR, France; SC, Scotland; SWE, Sweden; SWI, Switzerland; GDP, gross domestic 
product; PPP, purchasing power parity; OUP, out-of-pocket. 
a We defined ‘curative care’ as a combination of the Organization of Economic Cooperation and Development (OECD) health database categories: Services of 
curative and rehabilitative care, medical goods and ancillary services to healthcare. 
b The OECD database did not allow a breakdown in financing for curative care for England and Scotland (both United Kingdom), thus the data represents 
financing for a broader range of services (including long-term care and public health). 
c The data for the Netherlands has been corrected because the deductibles in the OECD data did not impute as private financing. 
d Following the OECD definition, out-of-pocket expenditure includes direct payments for care without insurance benefit, co-payments, co-insurance, and 
deductibles.
Source: OECD health data for 2011.31
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Cost-sharing (user charges) for covered services via 
deductibles or co-payments serve as thresholds in healthcare 
systems by making individuals responsible for a share of 
the costs. Cost-sharing varies considerably between the 8 
countries in our sample, as illustrated in Table 4. In 2014, 
the Netherlands and Switzerland were using a mandatory 
deductible of €360 and €250, respectively, but beneficiaries 
may opt for higher voluntary deductibles in exchange for 
lower premiums. Sweden uses a deductible of €122 for 
healthcare visits, €122 for prescription drugs and €333 for 
dental care. After these amounts, the government subsidy 
gradually increases up to 100% for prescription drugs and 
dental care. Children are waived from deductibles in these 3 
countries. All countries in our sample use co-payments within 
the publicly financed benefits package, either in percentage of 
costs for services rendered (Belgium, France, Scotland, and 
Switzerland) and/or fixed co-payments (England, Germany, 
the Netherlands, Sweden, and Switzerland). All countries in 
our sample also provide compensation to vulnerable groups 
such as elderly people or those with chronic disease.
Additional (Private) Insurance
All countries provide additional insurance with large 
differences in uptake by the population, ranging from <5% to 
90% (Table 5). These differences are partly explained by the 
system characteristics. England, Scotland, and Sweden have a 
low uptake of additional insurance due to automatic coverage 
in their NHS system. All countries provide supplementary 
insurance, while 3 countries (Belgium, Germany, and France) 
also provide complementary insurance. Complementary 
insurance refers to insurance that complements coverage 
of insured services (co-insurance) by covering all or part of 
the residual costs not otherwise reimbursed. Supplementary 
insurance provides coverage for additional health services 
not at all covered as essential health benefits. We identified 
annual premiums for regular additional benefits ranging 
from €150-912. However, such premiums are not always 
publicly reported, and we could therefore not establish 
reliable estimates. Countries with compulsory deductibles 
(the Netherlands and Switzerland) prohibit coverage of these 
deductibles via co-insurance. France raises nonrefundable co-
Table 4. Illustrations of Cost-Sharing Within Publicly Financed Healthcare
Compulsory Deductible Cost-Sharing (Co-payments and Co-insurance Above Maximum Reimbursement)
The Netherlands €360
~€95 medical transportation per year
€69 (<16 year) and €137.6 (≥16 year) orthopedic shoes per year 
€4 per hour maternity care
€20 per session with a psychologist
€32 per day for nonmedical maternity care
25% of the costs of a dental prosthesis
€125 for prosthesis or dental implant
25% of the price of a hearing aid
Belgium No
10%-40% co-payments for most services (depending on preferential reimbursement and service type)
Co-payments for medicines up to 80%, depending on reimbursement category and preferential 
reimbursement (0%-25%-50%-60%-80%); however the co-payments are maximized in some reimbursement 
categories
€40 for first hospital day; subsequently €13 per day; plus €0.62/day for medicines, €7.44 for biological 
testing/stay, €6.20 for radiology and €16.40/stay




€10 per hospital day or day at rehabilitation center (until max 28 days)




€240 for dental trajectory
Maximum: people who are not entitled to free subscriptions but expect to need more than 3 prescriptions 
in 3 months may opt for a prescription prepayment certificate at the cost of £104 per year. 
France €50a
20%-50% for different services: general practitioner, hospital, dentist, laboratory
Co-payments 85% for drugs according to category (0%-35%-65%-85%), depending on medical benefit and 
seriousness of the pathology 
Scotland No 80% dental costs with a maximum of €450
Sweden €122-333b
€11-22 per general practitioner visit
€25-35 per visit to a medical specialist 
€9 per hospitalization day
Cost-sharing for paramedic care and medical devices differ between regions
Maximum: €122 for general practitioner/medical specialist, €220 for devices, €600 for drugsc
Switzerland €250
10% for all services
€8 for hospital admission
Maximum: €570
Abbreviations: SHI, social health insurance; NHS, National Health Service. 
a Beneficiaries pay a deductible for a range of services (medicines, doctors, ambulance, hospital), which are deducted from reimbursement and are not insurable. 
b Medicines deductible €122; deductible for dental care €333.
c After the deductible amounts, the government subsidy gradually increases up to 100%. The maximum co-payment for prescribed drugs is €244 per year.
Sources: Health Systems in Transition, European Observatory on Health Care Systems; International Profiles of Health Care Systems 2012, The Commonwealth 
Fund; MISSOC; WHO Medicines Documentation (http://apps.who.int/medicinedocs/en/d/Jh2943e/11.3.html)
van der Wees et al
International Journal of Health Policy and Management, 2016, 5(1), 13–2218
payments for consultations and services up to €50 that cannot 
be covered with co-insurance.
Establishing Price and Regulating Volume
Establishing the price of healthcare services varies between 
countries, and can be set at the national level (Belgium, 
France, Scotland) or the regional level (Germany, Sweden, 
Switzerland), or a combination of the 2 (the Netherlands, 
England). In most countries, the price of healthcare services 
is established by (quasi)governmental agencies, except for the 
Netherlands and Switzerland. In the Netherlands, the price of 
70% of  hospital services is established via negotiations between 
individual insurers and individual provider organizations. In 
Switzerland, prices are mostly negotiated between insurer 
associations and providers at the regional level. Between 
countries, we identified differences in responsibilities at 
the national vs. the regional level for regulating volume. In 
France, while price is negotiated at the national level and 
approved by government, volumes are negotiated by insurers 
and providers; this is similar to the Netherlands. In Scotland, 
price is set at the national level, while volume constraints can 
be set by local NHS boards. Finally, in Sweden, volumes as 
well as prices are negotiated at the level of county councils.
Variations in Volume and Price
The actual use of healthcare services varies strongly between 
the 8 sample countries. Table 6 illustrates these differences 
for several healthcare services. These differences can be 
attributed to specific services that show large variations in 
practice. The OECD has studied such variations in practice 
for several procedures in various countries of our sample, 
showing for instance considerable variations in volume for a 
low-variety, sensitive condition such as total hip prosthesis.38 
Prices of healthcare services also vary between the countries 
in our sample.39 For example, a vignette study by the World 
Health Organization (WHO) shows considerably higher 
standardized costs for stroke services in the Netherlands 
(€7100) in comparison with England, France and Germany’s 
standardized costs of ~€4000. No major differences were 
found for the costs of total hip surgery with ~€6800 for this 
subset of countries.40,41
The relationship between health benefits and the financing of 
healthcare 
In previous paragraphs, we have described the 3 dimensions 
of publicly financed healthcare and variations in price and 
volume between the countries in our study. Our comparisons 
showed that virtually all residents in our sample of 8 counties 
are covered for basic health benefits (population coverage), 
which corresponds with the overall aim of European 
healthcare systems to provide accessible healthcare for all 
residents.42 
Our results also show that the scope of covered healthcare 
benefits is comparable across the countries in our sample. We 
found some examples of differences for coverage of dental 
care, physiotherapy, and prescription drugs. In assessing the 
financing of curative healthcare, we found a range of 7.4% to 
9.1% of GDP within the sample of our selected countries. The 
share of public financing of curative care ranges from 64.9% 
to 82.8%. At the macro level, we did not identify a pattern 
between the scope of services covered and the height of public 
financing. In other words, public financing of healthcare 
varied considerably between countries, while differences 
in covered healthcare benefits are relatively small. We did 
find substantial differences between the countries for cost-
sharing, and identified 2 main groups within our sample: low 
cost-sharing in England, France, Germany, the Netherlands 
and Scotland; and high cost-sharing in Belgium, Sweden and 
Switzerland. In regards to cost-sharing, we also found no clear 
relationship with the scope of services.
Potential Relationships at the Level of Specific Services  
We also assessed the potential relationships between service 
coverage and financing for specific services. Our comparisons 
indicated that the countries differed in details of service 
coverage in regards to dental care, physical therapy, and 
prescription drugs. We therefore specifically looked at the 
relationships between coverage and cost-sharing of these 
services.
Dental Care for Adults
Dental care for adults is not covered in the benefits package 
of Switzerland and the Netherlands. Of the 6 other countries 
in our comparisons, only Germany provides full coverage. 
The 5 remaining countries have substantial limitations in the 
coverage of dental care for adults. In Belgium, co-payments 
are set at 25%. Adult residents in England have to pay €240 
for a dental care service. In France, co-insurance varies from 
30% for routine dental care up to 90% for complex services 
such as orthodontic care. Scotland has implemented a co-
Table 5. Additional (Private) Insurance
Country %a Type Description
The Netherlands 85.0% Sb Coverage of dentist, physical therapy, eyeglasses, alternative medicine
Belgium 70.0% Cc/S Co-insurance; coverage of orthodontist, alternative medicine, private room
Germany 22.0% C/S Co-insurance (dental care); minor benefits, access to better amenities, private room
England 13.0% S Inpatient or day case surgery, hospital accommodation and nursing care, inpatient tests
France 90.0% C/S Co-insurance; private room, dental care, optical care
Scotland 8.5% S Private acute hospital care
Sweden <5.0% S Faster access to primary care services and shorter waits for surgery
Switzerland 90.0% S Coverage of dentist, private room, access to senior physicians, choice of hospital
a %: percentage of citizens with additional insurance.
b S: Supplementary insurance; provides coverage for additional health services not at all covered as essential health benefits.
c C: Complementary insurance; refers to insurance that complements coverage of insured services by covering all or part of the residual costs not otherwise 
reimbursed. 
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payment of 80% of the costs, with a maximum of €450. 
Sweden has implemented a deductible of €333 for dental 
care, and residents receive a subsidy of €16-32 for preventive 
dental services. With the exception of Germany, all countries 
in our sample have limited the actual coverage of dental care 
for adults. In the Netherlands and Switzerland, dental care 
for adults is not covered at all. In Belgium, England, France, 
Scotland, and Sweden, residents cover a substantial amount 
of the costs themselves. In other words, we found indications 
that the actual coverage for dental care is associated with cost-
sharing arrangements.
Physical Therapy
In the Netherlands, physical therapy is only reimbursed for 
a limited range of services: pelvic therapy for incontinence 
(women’s health), chronic conditions after the 20th treatment 
session (patients pay the first 20 sessions themselves), and for 
inpatient services. In England and Scotland, physical therapy 
services are covered in the public health service, although, 
and due to limited availability, a substantial amount of such 
services are offered in the private sector where patients have 
to pay themselves. In Belgium, various co-payments exist 
depending on the specific services, and may add up to 30% 
of the costs. Beneficiaries in Germany are charged a co-
payment of 10% plus €10 per visit. In France, the co-payment 
is 40%, and in certain circumstances insurance companies 
only provide reimbursement after they have given written 
permission. In Switzerland, insurance companies reimburse 
the first 9 treatment sessions within 3 months after referral to 
physical therapy services. The actual reimbursement depends 
on local prices. With the exception of England and Scotland, 
all countries in our sample have implemented limitations to 
service coverage or cost coverage. This suggests that the actual 
coverage of physical therapy services is associated with cost-
sharing arrangements.
Prescription Drugs
Prescription drugs are covered in the benefits package of all 
countries in our sample. In the Netherlands, Sweden, and 
Switzerland, prescription drugs are subject to deductibles. 
Beneficiaries in Switzerland are charged another 10% 
co-payment on top of the deductible, and Sweden has 
implemented co-payments ranging from 10%-50% of the 
costs, with a maximum of €600. In Belgium and France, 
co-payments can be as high as 80% and 85%, respectively. 
In Germany co-payment is €5-10 per prescribed drug, and 
in England co-payments are €10. Only residents in Scotland 
are not charged co-payments. This comparison shows that 
co-payments have been implemented in seven out of the 8 
countries in our sample. We found no associations between 
service coverage and cost-sharing. 
Discussion
At the most general level, we found no direct interrelationship 
between the ranges of services covered in the health benefits 
package, and the height of public spending on healthcare in 
our sample of 8 countries. By looking at specific services, 
we found limited associations between actual coverage of 
specific services and cost-sharing arrangements for these 
services. Access to certain specific healthcare services is either 
limited by the lack of actual coverage of such services, or by 
establishing thresholds to access via cost-sharing. Thresholds 
of cost-sharing can have a similar impact on the accessibility 
of healthcare services. Especially in countries with SHI, the 
uptake of additional insurance is high. Only few countries 
provide co-insurance for reimbursement of cost-sharing. 
The data in our sample of countries shows little variation in the 
scope of  benefits covered at the macro level. These findings 
are comparable with data from the United States which also 
showed little variation at the macro level between small 
group employer plans and state and federal plans, despite the 
relatively unregulated US market.43 An international survey 
to map health policy responses to the financial crisis showed 
that overall the statutory benefits package was not radically 
changed, but that some reductions were carried out, usually 
at the margin.1 At the macro level, it is difficult for policy-
makers to completely remove services from the essential 
health benefits package, because many services are beneficial 
to certain subgroups of patients.44 
The introduction or expansion of user charges is a more 
common policy measure at the macro level when trying to 
contain the cost of healthcare; many countries increased or 
introduced user charges for health services in response to the 
crisis.1 The RAND experiment already showed price elasticity 
between -0.17% and -0.22%, meaning that an increase of the 
price due to user charges leads to a reduction of the volume 
Table 6. Illustrations of Volume of Care in the 8 European Sample Countries
NL BE GEa FR UKb SWE SWI
Inpatient care discharges per 100 000 citizens per yearc 11 646 16 624 24 417 18 641 13 709 16 449 17 055
MRI-scans per 1000 citizens per year 49.9 77.0 95.2 67.5 - - -
CT scans per 1000 citizens per year 70.7 178.5 117.1 154.5 - - -
Surgical procedures per 100 000 citizens per year
Cataract surgery 856.6 1060.1 168.4 1077.6 664.7 848.1 437.7
Hip replacement 215.7 235.6 285.9 229.5 180.9 237.9 292.0
Coronary artery bypass 54.4 70.4 67.6 28.5 31.0 37.5 49.4
Doctor consultations per citizen per year 6.6 7.4 9.7 6.8 5.0 3.0 4.0
Dentist consultations per citizen per year 2.3 2.5 1.4 0.8 0.8 - 1.2
Abbreviations: NL, the Netherlands, BE, Belgium; GE, Germany; ENG, England; FR, France; SC, Scotland; SWE, Sweden; SWI, Switzerland.
a Additional data on the ambulatory care sector is not counted in these statistics. Additionally, only one code per procedure category per patient was counted. 
b Separate data for England and Scotland is lacking. 
c The number of patients that stayed in hospital at least one night.
Source: OECD Health Data 2013.31 Only the most recent data was used.
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of care; lower income groups were more price sensitive.12 
International research in a group of European countries 
showed that higher user charges lead to increased inequality 
between low and high incomes.45 The European Observatory 
concluded that cost sharing is unlikely to contribute to 
sustainability.46 If user charges are imposed, careful attention 
to the design of cost-sharing policy should be paid, which 
should be systematic and evidence-based.
Solutions for creating sustainable future financing of essential 
health benefits may be found at the micro level by stimulating 
evidence-based practice. In England, NICE has developed a list 
of ‘do not do’ recommendations derived from clinical practice 
guidelines, with the aim of excluding low-value services for 
certain subgroups.7 In the United States and Canada, the 
Choosing Wisely campaign for reducing unnecessary tests, 
treatment and procedures was started in 2012, and has 
grown into an international campaign.47 Choosing Wisely 
aims to promote conversations between clinicians and 
patients through evidence-based recommendations. These 
recommendations can be derived from existing clinical 
practice guidelines.48 
Unwarranted geographical practice variation in healthcare 
was set on the agenda by Wennberg as an important cost 
driver in healthcare.49 Unwarranted practice variation 
is a variation in utilization that cannot be explained by 
variation in patient illness or patient preferences.50 A recent 
systematic review identified large differences in the volume 
of healthcare between countries, regions, hospitals as well 
as individual healthcare providers.51 This may be caused by 
potential shortfalls in 3 areas: underuse of effective care, 
misuse in preference-sensitive care, and overuse of supply-
sensitive care. Several remedies have been described to reduce 
unwarranted variation, such as the implementation of clinical 
practice guidelines to stimulate evidence-based practice, 
increasing the role of patients in shared decision-making to 
optimize preference-sensitive care, and regulating resource 
capacity in the healthcare system to reduce supply-sensitive 
care. However, the implementation of such remedies requires 
more focus in health policy-making; additionally, the absence 
of economic incentives that reward providers for reducing 
unnecessary care is considered an important barrier.52
Most countries in our European sample control the price of 
care at the governmental level, except for the Netherlands 
and Switzerland, where most prices are negotiated between 
private insurers and provider organizations. These countries 
have created managed competition in their health insurance 
markets, which is somewhat analogous to the United States 
health insurance exchanges that are operated at the state 
and federal level. However, it is still unclear whether these 
mechanisms of competition will lead to reductions in the 
price and/or the volume of healthcare services.36
Implications for Policy
Although reducing the scope of the benefit package and 
increasing user charges may contribute to the financial 
sustainability of healthcare, variations in volume and price 
of care appear to have a much larger impact on financial 
sustainability. Our conclusions are confirmed by a recent 
assessment of the impact and policy implications of the 
economic crisis in Europe, highlighting that policy measures 
aimed at reducing the scope of the benefit package or 
increasing user charges, were only marginal.2 Moreover, 
countries did not report making changes to the benefits 
package based on evidence of cost-effectiveness.2 
In addition to the continuous evaluation of essential health 
benefits and cost-sharing arrangements, we suggest that other 
measures are needed to enhance the financial sustainability 
of healthcare regarding the volume and price of healthcare. 
Further insights into practice variations and establishing 
mechanisms to reduce unwarranted variation may contribute 
to enhancing the financial sustainability of healthcare. Supply 
constraints may have a much larger impact on reducing 
the volume of care, and thus on the long-term financial 
sustainability of public healthcare provision than limitations 
in service coverage.
For US policy-makers, our comparisons of European 
countries are useful for informing decision-making in 
regard to modifying the essential health benefits package 
framework. Monitoring the implementation is deemed 
essential to determine whether states’ differing strategies are 
producing the coverage improvements promised by reform. 
Officials have to assess whether enrollees are having a difficult 
time obtaining needed services because of gaps in coverage 
or the cost of care, and they have to modify the package 
accordingly.53 In the US context, with differing benefit 
packages and cost-sharing arrangements, a careful design of 
additional private insurance products warrants attention in 
terms of guaranteeing the sustainability of healthcare.
Limitations
Our study is subject to several limitations. First, the 3 
dimensions of healthcare (population coverage, service 
coverage, cost coverage) provide a simplification of statutory 
financed healthcare. The organizational and financial 
structure of healthcare is complex, and embedded in a wider 
societal structure with many more interactions. Second, due 
to the complexity of healthcare systems, comparisons across 
countries are subject to cautious interpretations. Although 
the dimensions of statutory financed healthcare that we 
used in our study are being employed in many international 
comparisons, such a model may not reflect the complexity 
of healthcare in our sample of countries. Third, our data 
analysis focused on the relationship between the scope of 
essential health benefits and statutory financing at the macro 
level, without disaggregating to differences at the micro level. 
Fourth, our sample of European countries was based on 
purposive sampling to reflect the variety existing in healthcare 
systems in Europe, and their main characteristics. Therefore, 
our sample does not provide a full picture of healthcare in 
Europe. Fifth, our study was explorative in nature, and did not 
allow for identifying causal relationships. 
Conclusion 
The scope of services covered in publicly financed healthcare 
is comparable and comprehensive across our sample of 8 
European countries, with only marginal differences. Cost-
sharing arrangements show larger variations. Considerations 
for the inclusion of services in the essential health benefits 
and for cost-sharing seem to evolve independently. 
However, cost-sharing implies thresholds for accessing 
van der Wees et al
International Journal of Health Policy and Management, 2016, 5(1), 13–22 21
specific health services. Both the scope of services and 
cost-sharing arrangements should be carefully monitored. 
Unwarranted practice variation and the price of healthcare 
services seem much larger drivers for the sustainability of 
healthcare. Our comparisons may not reflect the complexity 
of the healthcare system, and there is no silver bullet for 
addressing the sustainability of healthcare. Policy-makers 
should focus on a variety of measures within an integrated 
approach, including considerations for services covered, 
cost-sharing arrangements, additional private insurance, 
stimulating evidence-based practice, monitoring and 
reduction of unwarranted variation, and control mechanisms 
for the price of healthcare services. For policy-makers, our 
comparisons of European countries are useful for monitoring 
the implementation of essential health benefits, as well as to 
inform decision-making in regards to modifying the essential 
health benefits package framework.
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